November 21
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectSince its inception in 1956, the Auckland Cancer Society Research Centre (ACSRC) has published nearly 1,000 papers in international scientific and medical journals, and filed more than 100 patent applications for new anti-cancer drugs.
ViewHudson Institute of Medical Research is a leading Australian medical research institute recognised internationally for discovery science and translational research into reproductive health and pregnancy, infant and child health, inflammation and cancer.
ViewThe Institute for Innovation in Biotechnology (IIB) works in close association with the School of Biological Sciences (SBS) at the University of Auckland, and focuses on industry partnerships to accelerate innovation and develop new models of bioscience enterprise training.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn morePathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read morePolyActiva Showcases Promising Clinical Data Highlighting its Polymer Technology’s Potential to Transform Glaucoma Care
Read moreAravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Read morePhase III trial results of novel triple combination pill for hypertension published in The Lancet
Read more